Nanobiotix S.A. (NASDAQ: NBTX) will participate in the H.C. Wainwright Annual Global Investment Conference on September 15, 2026. The company’s management will take part in a fireside chat, giving investors a scheduled opportunity to hear directly from its senior executives.
Nano-X Imaging Ltd. (NASDAQ: NNOX) reported an additional U.S. distribution agreement and a Costa Rica distribution agreement supporting continued expansion across Latin America while holding $31.023 million in cash at June 30, 2026. The balance stood at $49.151 million on December 31, 2025. The …
National Vision Holdings, Inc. (NASDAQ: EYE) Chief Technology Officer David Cutler exercised options covering 12,998 shares on Sep. 8, 2026. The transaction left him with 12,998 shares, representing about 100.0% of his resulting share holding.
W. P. Carey Inc. filed a Form 8-K with the SEC on September 10, 2026, disclosing its year-to-date investment volume and an improved outlook for 2026 tenant credit related rent loss via a press release issued the same day.
ElectroCore, Inc. (NASDAQ: ECOR) appointed Joshua S. Lev and Michael Fox as co-Chief Executive Officers and Presidents, setting both executives’ annual base salaries at $540,000. Lev will retain his role as Chief Financial Officer, while Fox will continue as Chief Operating Officer. The appointments …
After the transaction, Anjaneya held 178,947 derivative securities, while the award represented about 38.2% of that resulting holding.
Evommune, Inc. (NYSE: EVMN) will stop developing EVO756 for atopic dermatitis after the treatment failed to meet the primary and secondary endpoints in its Phase 2b trial. The company will continue evaluating the oral MRGPRX2 antagonist in migraine prophylaxis.
Evommune, Inc. (NYSE: EVMN) plans to cease development of EVO756 for moderate-to-severe atopic dermatitis after its Phase 2b trial did not meet its primary and secondary endpoints at any dose studied. The company’s common stock had a reported sale price of $13.08 per share …
Evotec SE (NASDAQ: EVO) has moved JST-018, an investigational monoclonal-antibody cocktail against orthopoxviruses, into a first-in-human clinical study.
Gossamer Bio, Inc. (NASDAQ: GOSS) plans to reduce its authorized common shares from 4,000,000,000 to 50,000,000 as part of a reverse stock split and related capital-stock reduction. The measure is intended to help the biotechnology company regain compliance with Nasdaq’s minimum bid-price requirement, with …